TABLE 1

Demographics

Participants who completed the studyDropouts
Subjects9315
Male62 (67)9 (60)
Age years11.9±3.114.1±3.0*
STRA21 (23)2 (13)
Difficult asthma51 (55)8 (53)
Mild–moderate asthma21 (23)5 (33)
Atopic82 (88)13 (87)
Comorbidity17 (18)8 (53)*
Treatment
 Median ICS dose (BDP equivalent) μg·day−1800 (100–3200)1000 (200–2000)
 Leukotriene receptor antagonist55 (59)8 (53)
 Long-acting β-agonist91 (98)14 (93)
 Theophylline10 (11)2 (13)
 Maintenance OCS8 (9)2 (13)
 Omalizumab4 (4)0 (0)

Data are presented as n, n (%), mean±sd or median (range). STRA: severe therapy-resistant asthma; ICS: inhaled corticosteroid; BDP: budesonide propionate; OCS: oral corticosteroid. *: p<0.05.